McFarlane Neil F. 4

What Happened

Neil F. McFarlane, President, CEO and Director of Zevra Therapeutics (ZVRA), sold 91,000 shares in an open‑market transaction on Feb 2, 2026 for total proceeds of $853,425 (weighted average price $9.38). The Form 4 also reports derivative activity on Jan 31, 2026 (exercise/conversion of 233,334 derivative shares reported) and awards on Jan 29, 2026 (grants of 125,000 and 250,000 restricted stock units / derivative awards, and a stock option grant).

Key Details

• Primary sale: 91,000 shares disposed on 2026-02-02 at a weighted average price of $9.38; total proceeds reported $853,425. Trades executed at prices between $8.94 and $9.53 (weighted avg per filing).
• Derivative activity: 233,334 shares reported as an exercise/conversion on 2026-01-31 (the filing shows both an acquisition and a simultaneous disposal of 233,334 derivative shares at $0.00).
• Grants on 2026-01-29: 125,000 and 250,000 restricted stock units (RSUs) reported as awards (each RSU is a contingent right to one share per footnote).
• Option grant: Footnote indicates a stock option grant under the company’s equity plan (vesting in four equal annual installments per footnote).
• Vesting notes: Footnotes indicate RSUs vest and settle in installments (one‑third on 1/29/2027 and remaining in equal annual installments; another footnote states one‑third vested/settled on 1/31/2025 and 1/31/2026 with remaining on 1/31/2027).
• 10b5‑1 plan: Footnote shows a referenced 10b5‑1(c) plan adoption date of 03/21/2025.
• Filing detail: The sale was executed in multiple trades (F3) and the filer offers to provide granular trade information upon request. The provided filing did not list post‑transaction total shares beneficially owned.

Context

• Derivative explanation: The filing shows option/derivative exercises and RSU awards. When exercised/conversion entries are reported at $0 or as simultaneous acquisitions and disposals, that often reflects net share settlement, tax withholding, or internal settlement mechanics; the Form 4 here does not specify cash proceeds for those derivative disposals.
• Sale vs. purchase signal: The clear open‑market event is the Feb 2 sale for $853K. Sales are often routine (liquidity/tax/settlement) but do not necessarily signal management view of company prospects; RSU and option grants are compensation-related and not direct purchases of new economic exposure.
• Timeliness: No late‑filing flag was provided in the supplied data.

If you want, I can parse the likely post‑transaction ownership from the full Form 4 or request the detailed trade breakdown noted in the footnote.